Therapies targeting different pathogenic pathways in NASH are under investigation including nuclear receptor agonists like farnesoid X receptor (FXR), antioxidants, anti-inflammatory agents, antifibrotic agents, and modulators of the TNF-α pathway, among others.3,8,9. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.